Search results for "Prognostic"

showing 10 items of 316 documents

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA a…

2019

Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of ≥2 ACA, and a very CK (CK+) as ≥3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with <2 ACA (p=.09). Among patients wi…

MaleCancer Researchcomplex karyotypeANTHRACYCLINE MONOCHEMOTHERAPYmedicine.medical_treatmentAbnormal KaryotypechemotherapyGastroenterologyLeukocyte Count0302 clinical medicineLeukemia Promyelocytic AcuteRecurrenceAcute promyelocytic leukemiaAntineoplastic Combined Chemotherapy ProtocolsPROGNOSTIC-SIGNIFICANCECumulative incidenceATRAChildIn Situ Hybridization FluorescenceAged 80 and overrelapsePETHEMAIncidence (epidemiology)ADDITIONAL CHROMOSOME-ABNORMALITIESAge FactorsHematologyMiddle AgedPrognosisARSENIC TRIOXIDEFLT3 MUTATIONSLeukemiaTreatment OutcomeOncologyChild Preschool030220 oncology & carcinogenesisCytogenetic AnalysisFemaleAdultAcute promyelocytic leukemiamedicine.medical_specialtyCYTOGENETIC CHANGESAdolescentYoung Adult03 medical and health sciencesInternal medicineStatistical significanceComplex KaryotypemedicineHumansClinical significanceAgedCONSOLIDATION THERAPYChromosome AberrationsChemotherapybusiness.industrymedicine.diseaseRISK-ADAPTED TREATMENTTRANS-RETINOIC ACIDATRA Acute promyelocytic leukemia chemotherapy complex karyotype prognostic relapsebusinessprognostic030215 immunologyLeukemia & Lymphoma
researchProduct

Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience

2019

Many studies have reported a more favorable outcome in younger patients with Hodgkin lymphoma (HL). The aims of this study were to find an appropriate age cutoff able to identify low-risk children and to describe the natural history of 135 very young patients affected by classic HL (cHL). The best age cutoff was identified at 7 years of age. EFS (p = .0451) and PFS (p = .00921) were significantly better in the group of younger patients. The OS rate at 10 years was 97.0% in the younger group and 92.5% in the older one (p = .0448). However, age was not found to be an independent prognostic factor in multivariate analysis and the better prognosis in younger patients seems to be related to more…

MaleCancer Researchmedicine.medical_specialtyPrognostic factorMultivariate analysisAdolescent03 medical and health sciences0302 clinical medicineInternal medicineOutcome Assessment Health CaremedicineCutoffHumansPublic Health SurveillanceFavorable outcomeAge of OnsetChildchemotherapeutic approachesbusiness.industryAge FactorsDisease ManagementInfantHematologyPrognosisHodgkin DiseaseSurvival AnalysisNatural historypediatricOncologyItalyROC CurveSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA030220 oncology & carcinogenesisChild PreschoolLymphoma and Hodgkin diseaseHodgkin lymphomaDisease characteristicsFemalebusiness030215 immunology
researchProduct

Factors that predict response of patients with hepatitis C virus infection to boceprevir

2012

Background & Aims Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. Methods Previously untreated patients (from the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior therapy (from the Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 [RESPOND-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 28–48 wk). A good response to interfer…

MaleCirrhosisMESH: Logistic ModelsHepacivirusMESH: Risk AssessmentGastroenterologyPolyethylene GlycolsMESH: Recombinant ProteinsMESH: Genotype0302 clinical medicineOdds RatioProspective StudiesMESH: Treatment OutcomeResponse to Therapy0303 health sciencesMESH: Polymorphism Single NucleotideGastroenterologyvirus diseases3. Good healthMESH: RNA ViralHCVDrug Therapy Combination030211 gastroenterology & hepatologyClinical Trial; Genetic; Prognostic Factors; Response to Therapy; Adult; Antiviral Agents; Biomarkers; Canada; Drug Therapy Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukins; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism Single Nucleotide; Proline; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Viral Load; GastroenterologyViral loadmedicine.medical_specialtyMESH: InterleukinsGenotypeProlineInterferon alpha-2MESH: PhenotypeAntiviral AgentsRisk Assessment03 medical and health sciencesDrug TherapyGeneticMESH: RibavirinMESH: CanadaBoceprevirHumansPolymorphismMESH: ProlineMESH: HumansPrognostic FactorsInterleukinsMESH: AdultOdds ratiomedicine.diseaseUnited Statesdigestive system diseasesClinical trialLogistic ModelschemistryImmunologyMESH: FemaleBiomarkersTime Factorsmedicine.disease_causechemistry.chemical_compoundRisk FactorsInterferonMESH: Risk FactorsMESH: HepacivirusViralSingle NucleotideViral LoadHepatitis CClinical TrialRecombinant ProteinsEuropePhenotypeTreatment OutcomeCombinationRNA ViralFemaleMESH: Interferon-alphaMESH: Viral Loadmedicine.drugAdultMESH: Antiviral AgentsCanadaHepatitis C virusPolymorphism Single NucleotideMESH: Multivariate AnalysisInternal medicineRibavirinmedicineMESH: United States030304 developmental biologyMESH: Hepatitis CHepatologybusiness.industryRibavirinMESH: Time FactorsMESH: Biological MarkersInterferon-alpha[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Prospective StudiesMESH: MaleMESH: Odds RatioMESH: Drug Therapy CombinationMESH: Polyethylene GlycolsMultivariate AnalysisRNAInterferonsMESH: Europebusiness
researchProduct

Developing and validating a novel multisource comorbidity score from administrative data: a large population-based cohort study from Italy

2017

ObjectiveTo develop and validate a novel comorbidity score (multisource comorbidity score (MCS)) predictive of mortality, hospital admissions and healthcare costs using multiple source information from the administrative Italian National Health System (NHS) databases.MethodsAn index of 34 variables (measured from inpatient diagnoses and outpatient drug prescriptions within 2 years before baseline) independently predicting 1-year mortality in a sample of 500 000 individuals aged 50 years or older randomly selected from the NHS beneficiaries of the Italian region of Lombardy (training set) was developed. The corresponding weights were assigned from the regression coefficients of a Weibull sur…

MaleDatabases FactualKaplan-Meier Estimate030204 cardiovascular system & hematologySettore MED/42 - Igiene Generale E ApplicataSeverity of Illness IndexState MedicineCohort Studies0302 clinical medicineHealth careMedicineHospital Mortality1506Settore SECS-S/05 - Statistica Sociale030212 general & internal medicineMedical diagnosisAged 80 and overeducation.field_of_studyHealth Care CostsGeneral MedicineMiddle Agedprognostic scoreHospitalizationcomorbidityItalyadministrative databaseRegression AnalysisFemaleRisk AdjustmentPublic HealthCohort studyPopulationDrug PrescriptionsSettore MED/01 - Statistica Medica03 medical and health sciencesHumans1724Medical prescriptioneducationSurvival analysisAgedReceiver operating characteristicbusiness.industryResearchmedicine.diseaseComorbidityROC Curverecord linkagebusinessDemographyBMJ Open
researchProduct

Older women are frailer, but less often die then men: a prospective study of older hospitalized people

2019

Abstract Objectives The association between frailty, mortality and sex is complex, but a limited literature is available on this topic, particularly for older hospitalized patients. Therefore, the objective of our study was to prospectively evaluate sex differences in frailty, assessed by the Multidimensional Prognostic Index (MPI) and mortality, institutionalization, and re-hospitalization in an international cohort of older people admitted to hospital. Study design We used data from nine public hospitals in Europe and Australia, to evaluate sex differences in mortality, frailty and the risk of institutionalization and re-hospitalization, during one year of follow-up. Main outcome measures…

MaleGerontologyMultivariate analysisPrognosiLower riskArticleGeneral Biochemistry Genetics and Molecular BiologyHospital03 medical and health sciences0302 clinical medicineMultidimensional Prognostic IndexHumansMedicineLongitudinal StudiesProspective Studies030212 general & internal medicineProspective cohort studyGeriatric AssessmentAgedAged 80 and overSex Characteristics030219 obstetrics & reproductive medicineFrailtybusiness.industryMortality rateAustraliaObstetrics and GynecologyOdds ratioPrognosisHospitalsPatient DischargeConfidence intervalEuropeHospitalizationSurvival RateCohortSexFemaleCohort studybusinessCohort studyMaturitas
researchProduct

MARITAL STATUS IS A PROGNOSTIC FACTOR IN AMYOTROPHIC LATERAL SCLEROSIS

2017

Background and objectives Several variables have been linked to a shorter survival in patients with amyotrophic lateral sclerosis (ALS), for example, female sex, older age, site of disease onset, rapid disease progression, and a relatively short diagnostic delay. With regard to marital status, previous studies suggested that living with a partner might be associated to a longer survival and a higher likelihood to proceed to tracheostomy. Therefore, to further strengthen this hypothesis, we investigated the role of marital status as a prognostic variable in a cohort of ALS patients. Methods We performed a retrospective analysis on 501 consecutive ALS patients for which a complete disease's n…

MaleGerontologyPrognostic variablemedicine.medical_specialtyDisease03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineAmyotrophic lateral sclerosisAgedRetrospective StudiesMarital Statusbusiness.industryProportional hazards modelAmyotrophic Lateral SclerosisALS - marital status - survivalGeneral MedicineMiddle AgedPrognosismedicine.diseaseNatural historyNeurology030220 oncology & carcinogenesisCohortRegression AnalysisMarital statusFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessBody mass index030217 neurology & neurosurgery
researchProduct

Association of Antidementia Drugs and Mortality in Community-Dwelling Frail Older Patients With Dementia: The Role of Mortality Risk Assessment

2018

Objective: To evaluate whether treatment with antidementia drugs is associated with reduced mortality in older patients with different mortality risk at baseline. Design: Retrospective. Setting: Community-dwelling. Participants: A total of 6818 older people who underwent a Standardized Multidimensional Assessment Schedule for Adults and Aged Persons (SVaMA) evaluation to determine accessibility to homecare services or nursing home admission from 2005 to 2013 in the Padova Health District, Italy were included. Measurements: Mortality risk at baseline was calculated by the Multidimensional Prognostic Index (MPI), based on information collected with the SVaMA. Participants were categorized to …

MaleGerontologymedicine.medical_specialtyFrail ElderlyMultidimensional assessmentantidementia drugLower riskComprehensive geriatric assessmentRisk AssessmentArticle03 medical and health sciences0302 clinical medicineOlder patientsSDG 3 - Good Health and Well-beingRisk Factorsantidementia drugs; comprehensive geriatric assessment; Dementia; frailty; mortality; multidimensional prognostic index (MPI); Nursing (all)2901 Nursing (miscellaneous); Health Policy; Geriatrics and GerontologyInternal medicinemedicineHumansDementia030212 general & internal medicineMultidimensional prognostic index (MPI)MortalityGeriatric AssessmentNursing (all)2901 Nursing (miscellaneous)General NursingAgedRetrospective StudiesAged 80 and overFrailtybusiness.industryHealth PolicyHazard ratioGeneral Medicinemedicine.diseaseSurvival AnalysisConfidence intervalAntidementia drugs; Comprehensive geriatric assessment; Dementia; Frailty; Mortality; Multidimensional prognostic index (MPI); Nursing (all)2901 Nursing (miscellaneous); Health PolicyAntidementia drugsFemaleDementiaIndependent LivingGeriatrics and GerontologyNursing homesbusinessRisk assessment030217 neurology & neurosurgery
researchProduct

Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study

2015

Background: The clinical course of advanced adrenocortical carcinoma (ACC) is heterogeneous. Our study aimed primarily to refine and make headway in the prognostic stratification of advanced ACC.Patients and methods: Patients with advanced ENSAT ACC (stage III or stage IV) at diagnosis registered between 2000 and 2009 in the ENSAT database were enrolled. The primary end point was overall survival (OS). Parameters of potential prognostic relevance were selected. Univariate and multivariate analyses were carried out: model 1 'before surgery'; model 2 'post-surgery'.Results: Four hundred and forty-four patients with advanced ENSAT ACC (stage III: 210; stage IV: 234) were analyzed. After a medi…

MaleLung NeoplasmsENSATGastroenterologyPROPOSALClinical endpointAdrenocortical carcinomaENDOCRINEStage (cooking)Liver NeoplasmsIntraventricular blockHematologyMiddle AgedSERIESCANCEREuropeSurvival RateOncologymedicine.veinLymphatic MetastasisSURVIVALFemalemedicine.medical_specialtyUNITED-STATESBone NeoplasmsInferior vena cavaInternal medicineGRASmedicineadrenocortical carcinomaPrognostic factors adrenocortical carcinomaHumansNeoplasm InvasivenessSurvival rateAdrenocortical carcinoma; ENSAT; GRAS; Prognostic factors; Oncology; HematologyNeoplasm StagingRetrospective Studiesbusiness.industryCancerprognostic factorsRetrospective cohort studymedicine.diseaseAdrenal Cortex NeoplasmsSurgeryAdrenocortical carcinoma prognosisprognosisNeoplasm GradingNeoplasm Recurrence LocalbusinessFollow-Up StudiesAnnals of Oncology
researchProduct

Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: The outcome of incomplete resections

2013

The type of surgery (radical pleurectomy (RP) vs. extrapleural pneumonectomy (EPP)) remains controversial for malignant pleural mesothelioma (MPM). Macroscopic complete resection (MCR) is a key prognostic factor. It is unclear, if patients undergoing incomplete RP within a standardized multimodality treatment protocols have any advantage in terms of survival and if EPP could theoretically have avoided incomplete resections (R2).Eighty-eight patients underwent RP followed by chemoradiation from 2002 to 2011 within a prospective multimodality treatment study at a single institution. MCR were compared to R2 within this patient cohort retrospectively. EPP eligibility was assessed retrospectivel…

MaleMesotheliomaPulmonary and Respiratory MedicineExtrapleural PneumonectomyCancer Researchmedicine.medical_specialtyPrognostic factorLung NeoplasmsPleural NeoplasmsKaplan-Meier EstimateDisease-Free SurvivalmedicineHumansProspective StudiesStage (cooking)PneumonectomyAgedRetrospective StudiesProportional hazards modelPleural mesotheliomabusiness.industryMultimodality TreatmentMesothelioma MalignantChemoradiotherapyThoracic Surgical ProceduresCombined Modality TherapySurvival AnalysisSurgeryTreatment OutcomeOncologyCohortFemalebusinessPleurectomyhormones hormone substitutes and hormone antagonistsLung Cancer
researchProduct

Health-related quality of life is a prognostic factor for survival in older patients after colorectal cancer diagnosis: A population-based study

2015

International audience; Background: Studies carried out in the context of clinical trials have shown a relationship between survival and health-related quality of life in colorectal cancer patients.Aims: We assessed the prognostic value of health-related quality of life at diagnosis and of its longitudinal evolution on survival in older colorectal cancer patients. Methods: All patients aged >= 65 years, diagnosed with new colorectal cancer between 2003 and 2005 and registered in the Digestive Cancer Registry of Burgundy were eligible. Patients were asked to complete the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 at inclusion, three, six …

MaleMultivariate analysisColorectal cancerAppetiteDefinitions0302 clinical medicineQuality of lifeSurveys and QuestionnairesCancer registries030212 general & internal medicineAged 80 and overRelative survivalHazard ratioGastroenterologyScoresPrognosis3. Good healthSurvival RateOncology030220 oncology & carcinogenesisColonic NeoplasmsFemalePerspectivesmedicine.medical_specialtyPredict survivalClinical-TrialsContext (language use)Prognostic factorsFeeding and Eating DisordersAssociation03 medical and health sciencesInternal medicinePatient report outcomemedicineHumansMortalitySurvival rateAgedHepatologyRectal Neoplasmsbusiness.industryElderly-patientsCancer[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseElderly patientsQuality of LifePhysical therapyEuropean-organizationbusinessFollow-Up StudiesDigestive and Liver Disease
researchProduct